A CASE CHALLENGE IN HFrEF:

Case Study:

Case Study (cont)

Case Study: What Is the Next Step?

Stepwise Treatment for Symptomatic Patients With HF – NYHA II-IV

MRAs: Mechanism of Action

MRAs in HF

PARADIGM-HF Primary Results: Significant Reduction in Primary Endpoints, CV Death, and All-Cause Mortality

ESC Guidelines for HF: Therapeutic Algorithm for a Patient With Symptomatic HFrEF

RALES: Mortality Reduction With Spironolactone

PARADIGM-HF: Treatment Regimens

Gynecomastia With MRA Use in HF

Pathways Blocked by Pharmacological Therapies in HF

PARADIGM HF: Adverse Events With Sacubitril/Valsartan

PARADIGM- HF: Hyperkalemia With MRA Use -- Less Risk With Sacubitril/Valsartan

ESC Guidelines for HF: Pharmacological Treatments in Symptomatic (NYHA Class II-IV) HFrEF: Target Dosing

Early Benefit of Sacubitril/Valsartan

HF: A Lethal Progressive Disease

When Starting Sacubitril-Valsartan:

Abbreviations

Abbreviations (cont)